Streetwise Articles


Management Q&A: View from the Top

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way

Managment Q&A: View from the Top
  ()
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. read more >

Biotech's Launch of Pain Product Shows Encouraging Early Metrics

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset. read more >

Concurrent Milestones for Biotech Set to Occur 'on the Horizon'

Research Report
  ()
Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news. read more >

Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company

  ()
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. read more >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

  ()
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. read more >

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

  ()
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. read more >

Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. read more >

Biotech Round-Up: M&As, Financings and Immuno-Oncology

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. read more >

Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal

  ()
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. read more >

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data. read more >

Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick

Research Report
  ()
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status. read more >

Biotech Announces Positive Topline Data in Tourette Syndrome

Research Report
  ()
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. read more >

CMS Unexpectedly Issues Product Billing Code to Biotech

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm. read more >

RNAi Therapeutics Developer Reports Positive Amyloidosis Data

Research Report
  ()
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. read more >

Biotech Delivers 'Excellent' Phase 2 Data

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. read more >

Medical Device Firm Posts 'Strong Performance' Globally in Q4/17

Research Report
  ()
The company performed strongly in the U.S. and the Asia Pacific region. read more >

Regrouped Biotech's Stock Price Could See Fifteenfold Increase

Research Report
  ()
A recent conference call provided clinical and financial updates. read more >

Convergence Will Drive the Ultimate Disruption of Life Sciences

Contributed Opinion
  ()
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. read more >
Showing Results: 1 to 18 of 18

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe